PHR1624, Cisplatin, is soluble in water at 0.25g/100mL (up to 5mM) and in Dimethylformamide (DMF) at approximately 16mg/mL.
PHR1624
Cisplatin
Pharmaceutical Secondary Standard; Certified Reference Material
Synonym(s):
cis-Diammineplatinum(II) dichloride, cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Linear Formula:
Pt(NH3)2Cl2
CAS Number:
Molecular Weight:
300.05
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Pricing and availability is not currently available.
Recommended Products
grade
certified reference material
pharmaceutical secondary standard
Quality Level
Agency
traceable to Ph. Eur. C2210000
traceable to USP 1134357
API family
cisplatin
CofA
current certificate can be downloaded
packaging
pkg of 200 mg
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
mp
270 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-30°C
SMILES string
N.N.Cl[Pt]Cl
InChI
1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
InChI key
LXZZYRPGZAFOLE-UHFFFAOYSA-L
Looking for similar products? Visit Product Comparison Guide
General description
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Cisplatin is an antineoplastic drug used for the treatment of cancer patients with a variety of different malignancies.[1]
Cisplatin is an antineoplastic drug used for the treatment of cancer patients with a variety of different malignancies.[1]
Application
Cisplatin may be used as an analytical reference standard for the determination of the analyte in plasma, cancer cell, and tumor samples by high-performance liquid chromatographic assay.[2]
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Biochem/physiol Actions
Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.
Analysis Note
These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
Other Notes
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
Footnote
To see an example of a Certificate of Analysis for this material enter LRAB7778 in the slot below. This is an example certificate only and may not be the lot that you receive.
related product
Product No.
Description
Pricing
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
Target Organs
Respiratory system
Storage Class Code
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples.
Lopez-Flores A, et al.
Journal of Pharmacological and Toxicological Methods, 52(3), 366-372 (2005)
Sonja Ludwig et al.
Cancer immunology, immunotherapy : CII, 68(7), 1133-1141 (2019-05-30)
Advanced oral squamous cell carcinomas (OSCC) have limited therapeutic options. Although immune therapies are emerging as a potentially effective alternative or adjunct to chemotherapies, the therapeutic efficacy of combination immune chemotherapies has yet to be determined. Using a 4-nitroquinolone-N-oxide (4NQO)
Sample handling for determination of free platinum in blood after cisplatin exposure.
Johnsson A, et al.
Cancer Chemotherapy and Pharmacology, 41(3), 248-251 (1997)
Jessica M Rusert et al.
Cancer research, 80(23), 5393-5407 (2020-10-14)
Medulloblastoma is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most patients with medulloblastoma receive
Adrián E Granada et al.
Molecular biology of the cell, 31(8), 845-857 (2020-02-13)
DNA-damaging chemotherapeutics are widely used in cancer treatments, but for solid tumors they often leave a residual tumor-cell population. Here we investigated how cellular states might affect the response of individual cells in a clonal population to cisplatin, a DNA-damaging
-
What is the recommended solvent for Cisplatin, PHR1624? What is the solubility?
1 answer-
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
